Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + R-CHOP in EBV+ DLBCL
NCT04181489Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2019
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
sintilimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04181489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04181489.